Enterprise record

Jade Biosciences, Inc. logo

Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:cb88a14c-d296-4e95-b19a-2b3126726aa8Version: public-1As of: unavailable

12 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 5 claims
    • Legal Name: Jade Biosciences, Inc. · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 30, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 30, 2026

  2. DEF 14A d52810ddef14a.htm

    sec proxy · Source published: Apr 28, 2026 · Retrieved: Sep 2, 2026

    Supports 7 claims
    • Leadership Role: Andrew King: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Christopher Cain: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Eric Dobmeier: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Erin Lavelle: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Lawrence Klein: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Tom Frohlich: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Tomas Kiselak: Director · Claim reviewed: Sep 30, 2026